Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Retained-Blood Outcomes With Active Clearance Technology- The ACT Registry

NCT02682849 is registered in ClinicalTrials.gov with John M. Stulak as lead sponsor.

NCT NCT02682849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02682849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Retained-Blood Outcomes With Active Clearance Technology- The ACT Registry
Lead sponsor
John M. Stulak
Phase
Observational
Overall status
Completed
Start date
May 10, 2016
Completion date
March 31, 2020
Enrollment
500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retained blood syndrome